| Literature DB >> 19077228 |
Rita Depprich1, Holger Zipprich, Michelle Ommerborn, Christian Naujoks, Hans-Peter Wiesmann, Sirichai Kiattavorncharoen, Hans-Christoph Lauer, Ulrich Meyer, Norbert R Kübler, Jörg Handschel.
Abstract
BACKGROUND: Titanium and titanium alloys are widely used for fabrication of dental implants. Since the material composition and the surface topography of a biomaterial play a fundamental role in osseointegration, various chemical and physical surface modifications have been developed to improve osseous healing. Zirconia-based implants were introduced into dental implantology as an alternative to titanium implants. Zirconia seems to be a suitable implant material because of its tooth-like colour, its mechanical properties and its biocompatibility. As the osseointegration of zirconia implants has not been extensively investigated, the aim of this study was to compare the osseous healing of zirconia implants with titanium implants which have a roughened surface but otherwise similar implant geometries.Entities:
Mesh:
Substances:
Year: 2008 PMID: 19077228 PMCID: PMC2614983 DOI: 10.1186/1746-160X-4-30
Source DB: PubMed Journal: Head Face Med ISSN: 1746-160X Impact factor: 2.151
Figure 1Radiograph showing titanium (left) and zirconia (right) implants inserted into the tibia of minipigs after 12 weeks of healing time.
Figure 2Micrograph showing matrix-rich regeneration tissue (orange) between the implant and bone (green). Zirconia implant (left), titanium implant (right) (Masson-Trichrome-Goldner, 100-fold).
Figure 3At 4 weeks after implantation, osteoid and woven bone were formed both on zirconia (left) and titanium implant surfaces (right) (toluidine blue, 50-fold).
Figure 4After 12 weeks of healing, mature lamellar bone is evident in intimate contact with the zirconia implant (left) and titanium implant (right) (toluidine blue, 100-fold).
Figure 5Diagram depicting the increase in bone-to-implant contact (BIC) with time (1, 4, 12 weeks). No statistical significance was detected between the two treatment groups (p < 0.05).